Abstract
Aim
The present study aimed to investigate the effect of intravenous immunoglobulin (IVIG) on regulatory T (Treg) cells derived from immunosuppressed mice with Pseudomonas aeruginosa (PA) pneumonia.
Methods
A total of 108 BALB/c mice were randomly divided into the following groups: control group (Control), immunosuppressed group (IS), PA pneumonia group (PA), PA pneumonia in immunosuppressed group (IS + PA), PA pneumonia with IVIG treatment in immunocompetent group (PA + IVIG) and PA pneumonia with IVIG treatment in immunosuppressed group (IS + PA + IVIG). Each group comprised 18 mice. The combined PA pneumonia in immunosuppressed model and the treatment models were established. The mice in each group were sacrificed at 4, 8, and 24 h time points. The general condition and pathological changes in the lung tissues of the mice were monitored. Reverse transcription-polymerase chain reaction was used to detect the forkhead box P3 (FOXP3) mRNA relative expression level in the lung tissues. The enzyme-linked immunosorbent assay was used to detect the serum concentration of active transforming growth factor beta (TGF-β).
Results
No inflammatory response were exhibited in the lung tissues of the mice in Control group and IS group, while varying degrees of acute lung injury were revealed in the mice in PA group, IS + PA group, PA + IVIG group and IS + PA + IVIG group. Lung tissue injury was most apparent at the 8 h time point, and it indicated the greatest effect in IS + PA group. Whereas tissue damages were alleviated in PA + IVIG group and IS + PA + IVIG group compared with IS + PA group. In addition, tissue damage lessened in PA + IVIG group compared with PA group and IS + PA + IVIG group. FOXP3 mRNA expression levels in the lung tissues and the serum concentration of TGF-β were lower in IS group, PA group, IS + PA group and IS + PA + IVIG group at the 4, 8 and 24 h time points, respectively compared with Control group. FOXP3 mRNA expression levels decreased in PA + IVIG group at the 4h time point and TGF-β serum concentrations decreased at the 4 and 8h time points compared with Control group, and subsequently increased.
Figures
Citation: Li J, Chen T, Yuan C, Zhao G, xu M, Li X, et al. (2017) Effect of intravenous immunoglobulin on the function of Treg cells derived from immunosuppressed mice with Pseudomonas aeruginosa pneumonia. PLoS ONE 12(5): e0176843. https://doi.org/10.1371/journal.pone.0176843
Editor: Dennis W. Metzger, Albany Medical College, UNITED STATES
Received: November 16, 2016; Accepted: April 18, 2017; Published: May 8, 2017
Copyright: © 2017 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data underlying the result of the paper are within the Supporting Information files.
Funding: Support was provided by Basic and advanced technology research of Henan Province Science and Technology Department, Number: 142 300 410 327; [http://xm.hnkjt.gov.cn/]; and Medical science and technology research project of Henan Provience 201403060. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
The number of multidrug-resistant pathogens, such as Pseudomonas aeruginosa (PA) that can induce acute and chronic lung infection in immunosuppressed and/or immunodeficient patients is increasing annually worldwide [1,2,3]. The patients present with poor prognosis, although they frequently receive treatment with broad-spectrum antibiotics [4]. The underlying mechanisms are not completely understood. A majority of studies demonstrated that the function of the immune system was impaired in patients with autoimmune diseases. During disease recurrence and/or exacerbation stage, the function of regulatory T (Treg) cells is impaired and the dysfunction of the immune system occurs [5]. Treg cells are subsets of CD4+ T cells with specific immunosuppressive function that play an important role in the development of cancer, autoimmune and infectious diseases [6]. Treg cells suppress immune cell activation, inhibit inflammatory cytokine secretion and regulate immune responses via the expression of a specific transcription factor namely, forkhead box P3 (FOXP3). During this process Treg cells secrete various anti-inflammatory cytokines, such as transforming growth factor β (TGF-β) [7,8,9]. The defects of the immunosuppression process lead to immune response overactivation and rapid development of inflammatory diseases. The immunomodulatory capacity and anti-inflammatory effects are considered key properties of intravenous immunoglobulin (IVIG) that are encountered in primary immune deficiencies, immune thrombocytopenic purpura (ITP) and Kawasaki disease. The use of IVIG as a therapeutic regimen has been applied to a variety of autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Still’s disease and severe infections [10,11,12]. A recent study demonstrated that a combination of IVIG and antibiotics improved the prognosis of severely infected patients [13,14]. IVIG functions rely on two effective structural groups of the immunoglobulin molecule, namely, the F(ab’)2 fragment and the Fc fragment. The F(ab’)2 fragment mainly mediates receptor inhibition and cytokine production against pathogens and other noxious antigens, while the Fc fragment mediates modulation and/or inhibition of neonatal Fc receptor (FcRn) saturation and Fc gamma receptor (FcγR) expression. The Fc fragment is also related to the modulation of dendritic cells (DCs), the B cell and Treg cell function and the inhibition/scavenging of complement components [15]. IVIG can promote Treg cell function and the corresponding cytokines secretion, by modifying DCs phenotype to tolerogenic activity and promotion of the STAT5 expression. STAT5 is considered an essential molecule in Treg cell generation [16,17,18]. Based on these findings, the present study investigated the effects of IVIG on Treg cells derived from immunosuppressed mice with PA pneumonia, via the detection of FOXP3 mRNA expression level in lung tissue and the serum TGF-β concentration.
Materials and methods
The animal experiments were conducted in compliance with the institutional and federal guidelines regarding the use of animals in research and approved by the Animal Center of Zhengzhou University School of Medicine. In addition, the experimental protocols were reviewed and approved by the Medical Research Ethics Committee of the First Affiliated Hospital of Zhengzhou University.
Grouping and modeling
A total of 108 pathogen-free female BALB/c mice 6 to 8-weeks of age were purchased from the Animal Center of Zhengzhou University, School of Medicine. The animals weighted 25 to 45 g and were randomly divided into six groups, namely, control group (Control), immunosuppresed group (IS), PA pneumonia group (PA), PA pneumonia in immunosuppresed group (IS + PA), PA pneumonia with IVIG treatment in immunocompetent group (PA + IVIG) and PA pneumonia with IVIG treatment in immunosuppresed group (IS + PA + IVIG). All experimental mice were bred and maintained in a sterile animal facility with independent sterile bellows. The immunosuppressed model was established with an intermittent intraperitoneal injection of cyclophosphamide (CYP) (trade name: Endoxan; lot number: H20110407) at a dose of 150 mg per kg, as described in previous studies [19]. The control group received sterile physiological saline on days -5, -3, and -1. PA pneumonia was induced by intranasal instillation with PA suspension (10 μL for each nostril, 109 colony-forming units per mL) on day 0. The control group received sterile phosphate-buffered saline (PBS) suspension on day 0. A combined immunosuppression and PA pneumonia model was established. Following PA intervention on day 0, IVIG—mediated treatment models were immediately established by intraperitoneal injection of mice with 0.4 g per kg of IVIG (lot number: S10970032, purchased from Hualan Biological Engineering Inc). Following successful establishment of the models, six groups of mice were sacrificed at the 4, 8, and 24 h time points with administration of overdose anesthetic by intraperitoneal injection. Methods of grouping and modelling are shown in Fig 1.
Sample collection
The mice in each group were sacrificed for retro-orbital blood collection (0.8–1 mL). The blood was centrifuged for 15 min at 2,000 rpm. The collected supernatant was stored at –80°C for the estimation of the serum concentration of active TGF-β. Following the collection of the peripheral blood, the mice were disinfected in 75% alcohol. The left lung tissue was collected and stored at –80°C for the detection of the FOXP3 mRNA relative expression levels by reverse transcription—polymerase chain reaction (RT-PCR). The right lung tissue was fixed in 10% formalin, embedded in paraffin, sliced, and stained with hematoxylin and eosin (H&E) for histological analysis.
Detection index
Pathological score.
The right lung of the experimental mice was used for pathological H&E staining and scored by pathologists under a light microscope. Pathological scoring was based on a standard scoring system of acute lung injury [20], including alveolar congestion, pulmonary haemorrhage and/or pulmonary capillary congestion, pulmonary and vessel wall neutrophil accumulation and/or infiltration and alveolar wall thickening and/or hyaline membrane formation. Each side exhibited 5 levels according to the histological assessment: 0 (normal or very minor injuries), 1 (mild injury), 2 (moderate injury), 3 (severe injury) and 4 (very severe damage). The total score ranged between 0 and 20 points.
FOXP3 mRNA expression level.
The left lung tissue of the mice was homogenized in RNAase enzyme-free buernisher. Total RNA from lung tissues was extracted using the TRIzol method. It was measured and adjusted to the concentration of 500 ng per μL and the purity of 2.0 according to the A260/A280 ratio. Total cDNA was produced by reverse transcription via a Thermo Fisher reverse transcription kit (purchased from Thermo Fisher Scientific). qRT-PCR was carried out using a Thermo Fisher PCR kit with FOXP3 and glyceradehyde-3-phosphate-dehydrogenase (GAPDH) primers (synthesized by TaKaRa Biological Engineering Co., Ltd. Shanghai, China). GAPDH was used as an endogenous control. The reaction was carried out in a Thermo Fisher 7500 PCR light cycler. The PCR reaction conditions were as followed: an initial denaturation was conducted at 95°C for 3 min and subsequently 40 cycles of the 3 steps, namely, denaturation at 95°C for 35 s, annealing at 55°C for 35 s and extension at 72°C for 40 s. The final extension was conducted at 72°C for 5 min. The cycle threshold values were obtained for each group and calculated by the 2 (- ΔΔ CT) method in order to estimate the FOXP3 mRNA relative expression level. The primer sequences were as followed: GAPDH: forward primer: 5'GCACCGTCAAGGCTGAGAAC3'; reverse primer: 5'TGGTGAAGACGCAGTGGA3'; FOXP3: forward primer: 5'CCACTCCAGACAGAAGAAAGC 3'; reverse primer: 5'TCCAAGTCTCGTCTGAAGGC3 '.
TGF-β serum concentration.
The serum samples that were stored at –80°C were thawed at room temperature and the supernatant was collected following centrifugation at 3,000 rpm for 5 min. The samples were heated in a water bath at 80°C for 8 min and cooled for 5 min. The kit was kept at room temperature for 30 min, according to the manufacturer’s instructions (purchased from Dake Biotechnology Co., Ltd.) in order to estimate the serum concentration of active TGF-β. Each sample was tested in triplicate. The fluorescence of each well was measured using a microplate reader. The serum concentration of active TGF-β was determined by comparison with a standard curve.
Statistical analysis
Data were analyzed using SPSS17.0 (SPSS, IL, USA). The values were expressed as mean ± SD. The quantification data were assessed using the least significant difference (LSD) method of one-way analysis of variance and Bonferroni’s test was carried out for the comparison between different groups. A P value of less than 0.05 (P<0.05) was considered statistically significant.
Results
General condition and manifestation
The general condition of the mice did not change significantly following the induction of the models (including mental status, weight, activities, and the amount of food and drinking water) in Control group and IS group. And the lung tissue was pink and shiny with no bleeding or pus observed by visual investigation in the mice in Control group and IS group. But varying degrees of listlessness, reduced activities, reduced food and water consumption, weight loss, and yellow color of the coat were indicated in the mice in PA group, IS + PA group, PA + IVIG group and IS + PA + IVIG group. Their lung tissue was dark and reluster. Varying degrees of bleeding and pus were visible on the surface of lung in PA group, IS + PA group, PA + IVIG group and IS + PA + IVIG group. Whereas greater severity in terms of tissue damage were indicated in mice in IS + PA group.
Histopathological analysis of lung tissue
Light microscopic analysis revealed that normal lung tissue structures without obvious lung injury were exhibited in the mice in Control group and IS group at the three time points (4, 8 and 24 h). However, varying degrees of acute lung injury were exhibited in the mice in PA group, IS + PA group, PA + IVIG group and IS + PA + IVIG group at the 4 h time point. The injury exhibited the greatest severity at the 8 h period, and the most severe injuries were displayed in the mice in IS + PA group. Severe pulmonary capillary congestion, massive pulmonary haemorrhage, neutrophil infiltration, alveolar wall thickening and/or breaking and alveolar hyaline membrane formation were indicated in the mice in IS + PA group. After treatment with IVIG, less lung injury was exhibited in the mice in IS + PA + IVIG group compared with IS + PA group. Capillary congestion, pulmonary bleeding, moderate infiltration of neutrophils and alveolar wall thickening and/or breaking were exhibited in the mice in IS + PA + IVIG group. Similarly, lesser lung injury was indicated in the mice in PA + IVIG group compared with PA group. Apparent capillary congestion, a low-to-moderate amount of red blood cell leakage in the lungs, neutrophil infiltration and partial alveolar wall thickening in the absence of hyaline membrane formation were exhibited in the mice in PA group. Mild lung injury including neutrophil infiltration in several local tissues, a small amount of red blood cell leakage and thickened alveolar walls were exhibited in the mice in PA + IVIG group. The acute lung damages were alleviated in PA group, PA + IVIG group and IS + PA + IVIG group at the 24 h time point, while a severe injury in the absence of improvement was indicated in IS + PA group. The comparison of different groups at the same time point revealed that with the exception of PA group, IS + PA group, PA + IVIG group and IS + PA + IVIG group at the 4h time point, as well as Control group and IS group at the three time points (4, 8 and 24 h), the differences among the remaining groups were statistically significant (P < 0.05). The comparison of the same group at different time points revealed that with the exception of Control group and IS group at the three time points (4, 8 and 24 h), IS + PA group at the 8 and 24 h time points and PA + IVIG group at 4 and 8h time point, the differences observed in the remaining groups were statistically significant (P < 0.05). The lung histopathological manifestations of the lung tissues at 8 h in each group are shown in Fig 2, and the pathological scores in each group are shown in Fig 3.
Six groups were studied: Control group (A), IS group (B), PA group (C), IS + PA group (D), PA + IVIG group (E) and IS + PA + IVIG group (F). Immunosuppression was induced on day -5, -3 and -1 by intraperitoneal injection of CYP, PA pneumonia was induced on day 0 and IVIG mediated treatment models were immediately established following PA intervention on day 0. Following establishment of the models, mice were sacrificed at the 4, 8, and 24 h time points. The right lung tissue was fixed in 10% formalin, embedded in paraffin, sliced, and stained with H&E for histological analysis. Histopathological manifestations of lung tissue in six groups at 8h were shown with magnified 100 times.
Six groups were studied: Control group, IS group, PA group, IS + PA group, PA + IVIG group and IS + PA + IVIG group. Immunosuppression was induced on day -5, -3 and -1 by intraperitoneal injection of CYP, PA pneumonia was induced on day 0 and IVIG mediated treatment models were immediately established following PA intervention on day 0. The right lung of the experimental mice was used for pathological analysis and scored based on a standard scoring system of acute lung injury. Pathological scores of lung tissue in six groups at 4, 8 and 24h were shown.
FOXP3 mRNA relative expression levels in lung tissues
FOXP3 mRNA relative expression levels did not show significant changes in Control group at the three time points (4, 8 and 24 h). However, FOXP3 mRNA relative expression levels were down-regulated in IS group, PA group, IS + PA group, PA + IVIG group and IS + PA + IVIG group at the 4 h time point. This effect was greater in IS + PA + IVIG group and lesser in IS group. FOXP3 mRNA levels tended to increase in PA group, PA + IVIG group and IS + PA + IVIG group, with the exception of IS group and IS + PA group at the 8 and 24 h time points. FOXP3 mRNA relative expression levels were indicated down-regulated in IS group at the three time points compared with Control group. This demonstrated that CYP may inhibit Treg cellular proliferation and suppressive function. However, FOXP3 mRNA relative expression levels were lower in IS + PA group compared with IS group at the 4, 8 and 24 h time points, which suggested that the down-regulation of Treg cells in immunosuppressed mice with PA pneumonia was notably associated with the impaired immune system, rather than with the intervention of CYP alone. Following treatment with IVIG, FOXP3 mRNA relative expression levels were higher in IS + PA + IVIG group compared with IS + PA group at 8 and 24h. Similarly, higher FOXP3 mRNA relative expression levels were indicated in PA + IVIG group compared with PA group at 8 and 24h. The data suggested that IVIG modulated the immune response by promoting Treg cells function and/or proliferation. The comparison of different groups at the same time point demonstrated that the differences exhibited statistical significance (P < 0.05), with the exception of the following: PA group and IS + PA + IVIG group, PA group and PA + IVIG group, IS + PA group and IS + PA + IVIG group at the 4 h time point, PA group and IS group at the 8 h time point, Control group and PA + IVIG group, as well as IS group and IS + PA + IVIG group at the 24 h time point. The comparison in the same group at different time points revealed that with the exception of Control group and IS group at the three time points (4, 8 and 24 h) and IS + PA group at 4 and 8h time points, the differences were statistically significant for the remaining groups (P < 0.05). The FOXP3 mRNA relative expression levels in the lung tissues are shown in Fig 4.
Six groups were studied: Control group, IS group, PA group, IS + PA group, PA + IVIG group and IS + PA + IVIG group. Immunosuppression was induced on day -5, -3 and -1 by intraperitoneal injection of CYP, PA pneumonia was induced on day 0 and IVIG mediated treatment models were immediately established following PA intervention on day 0. The left lung tissue of the mice was used for testing FOXP3 mRNA relative expression by qRT-PCR. qRT-PCR was carried out using a Thermo Fisher PCR kit with FOXP3 and GAPDH primer. FOXP3 mRNA relative expression level was calculated by the 2 (- ΔΔ CT) method. FOXP3 mRNA expression levels in lung tissue in six groups at 4, 8 and 24h were shown.
Serum concentration of active TGF-β
TGF-β can be secreted in latent or active forms, although the serum concentration of latent TGF-β is considerably low. The serum concentration of active TGF-β was tested following heating of the samples to induce activation of the TGF-β protein. The serum concentration of TGF-β in the peripheral blood exhibited no apparent change in Control group at the three time points. The concentrations of TGF-β were reduced in IS group, PA group, IS + PA group, PA + IVIG group and IS + PA + IVIG group compared with that noted in Control group at the 4 and 8 h time points. An increase was demonstrated at the 24 h time point in PA group, PA + IVIG group and IS + PA + IVIG group. The increased concentration of TGF-β was considerably high in PA + IVIG group, while it lessened in PA group and IS + PA group. The down-regulated TGF-β concentration in IS group did not change at the three time points, indicating the persistent suppression of Treg cells by CYP. However, the concentrations of TGF-β were considerably lower in IS + PA group compared with that noted in IS group at the three time points. This finding indicated that the suppression of Treg cell function in immunosuppressed host with PA pneumonia was notably associated with an impairment of the immune system, rather than a pharmacological effect caused by intervention of the animals with CYP alone. In addition, the concentration of TGF-β was higher in IS + PA + IVIG group compared with IS + PA group at the 24h time point, whereas higher concentration of TGF-β were exhibited in PA + IVIG group compared with PA group at the 24h time point, following treatment with IVIG. These findings indicated that IVIG may improve Treg cell function. The comparison of the different groups at the same time point demonstrated that with the exception of the 4 h time point in IS + PA group and IS + PA + IVIG group, the 4 h time point in PA group, IS group and PA + IVIG group, the 8h time point in PA group and IS + PA + IVIG group, the 8h time point in PA group and PA + IVIG group, the 8 h time point in IS + PA group and IS + PA + IVIG group, the 24 h time point in Control group and PA + IVIG group and the 24 h time point in PA group and IS group, differences among the remaining groups were statistically significant (P < 0.05). The comparisons of the same groups at different time points indicated that with the exception of Control group and IS group at the three time points and IS + PA group at the 8 and 24 h time points, the differences noted were statistically significant for the remaining groups (P < 0.05). The serum concentrations of active TGF-β are shown in Fig 5.
Six groups were studied: Control group, IS group, PA group, IS + PA group, PA + IVIG group and IS + PA + IVIG group. Immunosuppression was induced on day -5, -3 and -1 by intraperitoneal injection of CYP, PA pneumonia was induced on day 0 and IVIG mediated treatment models were immediately established following PA intervention on day 0. Serum samples were heated in a water bath at 80°C for 8 min and cooled for 5 min. The serum concentration of active TGF-β was tested by ELISA kit and was determined by comparison with a standard curve. Serum concentrations of active TGF-β in six groups at 4, 8 and 24h were shown.
Discussion
Treg cells were identified as subsets of CD4 + T cells [21], which play important roles in the regulation of immune tolerance, immunosuppression, development of inflammation and tumour [7]. Treg cells can secrete a large amount of anti-inflammatory cytokines such as, IL-10, TGF-β and IL-35. TGF-β is one of the major effectors of Treg cells. It is also secreted by B cells, macrophages, and DCs. It promotes Treg cell differentiation and FOXP3 expression. The interaction between TGF-β and FOXP3 plays an important role in the maintenance of immune tolerance [22]. FOXP3 is a transcription factor, specifically expressed in Treg cells. It can induce Treg cell differentiation, promote cell proliferation and stabilize the expression of multiple cell surface molecules in T cells express antigen receptors (TCR) -dependent manner. It can also inhibit the secretion of a variety of pro-inflammatory cytokines [9]. To date, a limited number of studies have focused on Treg cell function in pneumonia, notably in pneumonia under immunosuppressed conditions. Treg cells were shown to alleviate lung injury by the modulation of the immune response, although the underlying mechanism remains unclear [23].
IVIG replacement therapy was applied to congenital primary immunodeficiency disease for the first time in the 1950s [24]. IVIG is now widely used in the treatment of autoimmune diseases, primary or secondary immunodeficiency diseases, and severe infections [10,11,25]. The primary action of immunoglobulins mainly relies on two segments, the F(ab’)2 and the Fc portion. The F(ab’)2 portion mediates inhibition of the receptors, antibodies and cytokines, while the Fc portion is associated with saturation of FcRn, modulation of FcγR expression, modulation of DCs and B cells and inhibition and/or clearance of the complement components [15,26]. Immunoglobulins further promote production of Treg cells and immune-suppressive function. Immunoglobulins may modulate the number of Treg cells by modification of the DC phenotype to immature or tolerogenic DCs and promotion of STAT5 expression, an essential molecule related to the production of Treg cells [17]. They also increase Treg cells suppressive potency by increasing the percentage of Treg cells in the CD4 population and/or by increasing the percentage of Treg cells expressing IL-10, as well as promoting FOXP3 expression and the secretion of effector molecules [18]. However, the effects of immunoglobulins to Treg cells in the immunosuppressed host with PA pneumonia remain unclear.
CYP is a cytotoxic alkylating agent that is widely used for the treatment of neoplastic disease and severe autoimmune diseases. CYP is widely used in the establishment of the immunosuppressed animal model [27]. Studies on CYP have demonstrated that the compound inhibits Treg cell production and suppressive function by the following modes of action: ablation of the DCs involved in peripheral tolerance, interference with homeostatic proliferation of Treg cells, increase in the susceptibility of Treg cells to apoptosis, decrease of the suppressive effectors of FOXP3 experssion and reduction of the expression of CD25, a critical factor for the growth of Treg cells [28,29]. Despite the aforementioned findings, the association of the inhibition of Treg cells in immunosuppressed host with PA pneumonia with the effect caused by CYP remains unkown.
FOXP3 mRNA expression levels in the lung tissues and the concentration of TGF-β in serum, were decreased slightly in the CYP -induced IS mice compared with Control mice (Figs 4 and 5). Furthermore, in PA mice, histopathological analysis exhibited moderate lung injury (Fig 2B). FOXP3 mRNA expression levels in lung tissues were reduced at the 4 h time point, while they increased at the 8 and 24 h time points (Fig 4). The concentration of TGF-β in serum decreased at the 4 and 8 h time points and increased at the 24 h time point (Fig 5). The increased tendency of FOXP3 mRNA expression levels and the concentration of TGF-β in the serum indicated that Treg cells in PA mice may be timely activated by the immune system during homeostasis. However, it was observed that PA pneumonia in immunosuppressed mice developed rapidly and was uncontrolled compared with normal mice. PA pneumonia—induced lung injury was severe in IS + PA mice (Fig 2D). In addition, FOXP3 mRNA expression levels in lung tissues and the concentration of TGF-β in the serum were significantly reduced compared with IS mice and PA mice (Figs 4 and 5). This finding indicated that in IS + PA mice, the population of Treg cells was greatly inhibited due to the disturbed immune system and not due to CYP intervention or PA infection alone. Following 4 h of IVIG treatment, the expression levels of FOXP3 mRNA in the lung tissues increased (Fig 4). Following 8 h of IVIG treatment, the peripheral blood concentrations of TGF-β increased (Fig 5), and the lung tissue damage was also alleviated (Fig 2E and 2F). Following 24 h of IVIG treatment, the lung injury was considerably alleviated. The results suggested that in the IS + PA mice, the Treg cell function was apparently impaired and the immune responses were disordered. A previous study demonstrated that Th17 cells were overactivated and secreted excessive pro-inflammatory cytokines that resulted in organ damage in the immunosuppressed and PA pneumonia model. However, the immunomodulatory capacity of Treg cells was impaired that in turn strengthened the immune response and promoted the development of the disease. Following IVIG treatment, the activation of Th17 cells was partially inhibited and the immunosuppressive functions of the Treg cells were amplified. Consequently, this process promoted the restoration of the function of the immune system and the alleviation of the development of the disease.
In conclusion, the data demonstrated that the immune system was compromised and the immunomodulatory capacity of the Treg cells was impaired persistently in the immunosuppressed model with PA pneumonia. The overactivation of the immune response without suppression and the infiltration of the immune cells in the lung tissue caused severe tissue damage and resulted in rapid development of the disease. Nevertheless, following IVIG treatment, the immune system impairment was ameliorated and the immunosuppressed functions of Treg cells were partially restored. This process resulted in considerably less tissue damage and promoted disease recovery. Consequently, the use of IVIG in the regulation of the immune response and the restoration of the immunosuppressed function may be a powerful tool to treat immunocompromised patients with infections.
Author Contributions
- Conceptualization: LX JL.
- Data curation: JL TC.
- Formal analysis: JL TC.
- Funding acquisition: LX.
- Investigation: GZ JL CY MX XL JC.
- Methodology: TC JL.
- Project administration: LX TC JL.
- Resources: MX GZ.
- Software: JL TC.
- Supervision: LX.
- Validation: LX JL.
- Visualization: TC JL CY XL JC.
- Writing – original draft: JL LX TC.
- Writing – review & editing: LX JL.
References
- 1. Hill NS. Noninvasive ventilation for immunocompromised patients. N Engl J Med. 2001; 344(7): 522–4. pmid:11172197
- 2. Gao Jing, Zhang Lei, Zhang Xin, Zhao Shi-long, Liu Sheng-yun, Xing Li-hua. Level of Serum Procalcitonin and C-Reactive Protein for Evaluating Pulmonary Bacterial Infection in Patients with Lupus Erythematosus. J Huazhong Uni Sci Technol. 2016; 36(5): 653–658.
- 3. Restagno D, Venet F, Paquet C, Freyburger L, Allaouchiche B, Monneret G, et al. Mice Survival and Plasmatic Cytokine Secretion in a "Two Hit" Model of Sepsis Depend on Intratracheal Pseudomonas Aeruginosa Bacterial Load. PLoS One. 2016; 11(8): e0162109. pmid:27574993
- 4. Yayan J, Ghebremedhin B, Rasche K. Antibiotic Resistance of Pseudomonas aeruginosa in Pneumonia at a Single University Hospital Center in Germany over a 10-Year Period. PLoS One. 2015; 10(10): e0139836. pmid:26430738
- 5. Lu P, Cao Y, Wang M, Zheng P, Hou J, Zhu C, et al. Mature dendritic cells cause Th17/Treg imbalance by secreting TGF-β1 and IL-6 in the pathogenesis of experimental autoimmune encephalomyelitis. Cent Eur J Immunol. 2016; 41(2): 143–52. pmid:27536199
- 6. Schmidt A, Eriksson M, Shang MM, Weyd H, Tegnér J. Comparative Analysis of Protocols to Induce Human CD4+Foxp3+ Regulatory T Cells by Combinations of IL-2, TGF-beta, Retinoic Acid, Rapamycin and Butyrate. PLoS One. 2016; 11(2): e0148474. pmid:26886923
- 7. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004; 22: 531–62. pmid:15032588
- 8. Kashima H, Momose F, Umehara H, Miyoshi N, Ogo N, Muraoka D, et al. Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS One. 2016; 11(6): e0156643. pmid:27284967
- 9. Tai X, Erman B, Alag A, Mu J, Kimura M, Katz G, et al. Foxp3 transcription factor is proapoptotic and lethal to developing regulatory T cells unless counterbalanced by cytokine survival signals. Immunity. 2013; 38(6): 1116–28. pmid:23746651
- 10. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system. Nat Rev Immunol. 2013; 13(3): 176–89. pmid:23411799
- 11. Cattepoel S, Gaida A, Kropf A, Nolte MW, Bolli R, Miescher SM. Effect of IVIG Formulation on IgG Binding to Self- and Exo- Antigens In Vitro and In Vivo. PLoS One. 2016; 11(8): e0161826. pmid:27561008
- 12. Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev. 2015; 14(8): 651–8. pmid:25870941
- 13. Schedel I, Dreikhausen U, Nentwig B, Höckenschnieder M, Rauthmann D, Balikcioglu S, et al. Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med. 1991; 19(9): 1104–13. pmid:1884609
- 14. Rodríguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock. 2005; 23(4): 298–304. pmid:15803051
- 15. Zuercher AW, Spirig R, Baz MA, Käsermann F. IVIG in autoimmune disease—Potential next generation biologics. Autoimmun Rev. 2016; 15(8): 781–5. pmid:27019051
- 16. Kaufman GN, Massoud AH, Dembele M, Yona M, Piccirillo CA, Mazer BD. Induction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate Immunity. Front Immunol. 2015; 6: 469. pmid:26441974
- 17. Lee SY, Jung YO, Ryu JG, Kang CM, Kim EK, Son HJ, et al. Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an interleukin-10-dependent manner. Arthritis Rheumatol. 2014; 66(7): 1768–78. pmid:24644005
- 18. Massoud AH, Guay J, Shalaby KH, Bjur E, Ablona A, Chan D, et al. Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3-positive regulatory T cells. J Allergy Clin Immunol. 2012; 129(6): 1656–65.e3. pmid:22564681
- 19. Tingsang Chen, Congcong Yuan, Lihua Xing. Animal models of Pseudomonas aeruginosa pneumonia. Int J Respir. 36. 2016; 36(6): 445–7.
- 20. Su ZQ, Mo ZZ, Liao JB, Feng XX, Liang YZ, Zhang X, et al. Usnic acid protects LPS-induced acute lung injury in mice through attenuating inflammatory responses and oxidative stress. Int Immunopharmacol. 2014; 22(2): 371–8. pmid:25068825
- 21. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995; 155(3): 1151–64. pmid:7636184
- 22. Travis MA, Sheppard D. TGF-β activation and function in immunity. Annu Rev Immunol. 2014; 32: 51–82. pmid:24313777
- 23. Odeh AN, Simecka JW. Regulatory CD4+CD25+ T Cells Dampen Inflammatory Disease in Murine Mycoplasma Pneumonia and Promote IL-17 and IFN-γ Responses. PLoS One. 2016; 11(5): e0155648. pmid:27175511
- 24. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am. 2008; 28(4): 737–64, viii. pmid:18940572
- 25. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2007; 35(12): 2686–92. pmid:18074465
- 26. Basta M, Branch DR. 7th International Immunoglobulin Conference: Mechanisms of action. Clin Exp Immunol. 2014; 178 Suppl 1: 111.
- 27. Manepalli S, Gandhi JA, Ekhar VV, Asplund MB, Coelho C, Martinez LR. Characterization of a cyclophosphamide-induced murine model of immunosuppression to study Acinetobacter baumannii pathogenesis. J Med Microbiol. 2013; 62(Pt 11): 1747–54. pmid:24000227
- 28. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 2012; 72(14): 3439–44. pmid:22761338
- 29. Radojcic V, Bezak KB, Skarica M, Pletneva MA, Yoshimura K, Schulick RD, et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother. 2010; 59(1): 137–48. pmid:19590872
